Article | June 13, 2023

7 Facts About Antibody Drug Conjugates

By Brian Moloney, Director New Products & Innovation

Antibody-drug-human-system-GettyImages-824641956

Antibody drug conjugates (ADCs) have the potential to destroy cancerous cells without damaging healthy cells in the process, making them a growing field of interest in biopharmaceutics. Several ADCs are already successfully used in the treatment of myeloid leukemia or refractory metastatic breast cancer. Many others are in clinical trials and waiting for their FDA approval.

Learn the details behind different components and functions of ADCs and seven facts you probably didn't know yet about antibody drug conjugates and how they are advancing therapeutics.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online